Rezolute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RZLT research report →
Range $6 – $14
Price Chart
About the company
Rezolute, Inc. , a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
- CEO
- Nevan Charles Elam
- IPO
- 2013
- Employees
- 68
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on RZLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $448.72M
- P/E
- -5.68
- Fwd P/E
- 2.72
- PEG
- -0.16
- P/S
- 0.00
- P/B
- 4.15
- EV/EBITDA
- -5.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.82%
- ROIC
- -73.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-79,894,000
- Net Income
- $-74,412,000-8.7%
- EPS
- $-0.98+26.3%
- OCF Growth
- -20.4%
- FCF Growth
- -20.4%
- 52W High
- $11.46
- 52W Low
- $1.07
- 50D MA
- $4.76
- 200D MA
- $4.42
- Beta
- 0.62
- RSI (14)
- 48
- Avg Volume
- 1.78M
No earnings-call transcripts are available for RZLT yet.
- Free Float
- 68.5%
- Shares Outstanding
- 96.29M
- Float Shares
- 66.01M
of shares held by institutions
137 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.79M | ▲ 378.43K |
| Point72 Europe (London) Llp | 127.74K | ▲ 89.21K |
| Allostery Investments LP | 119.29K | ▲ 119.29K |
| Cwm, LLC | 55.80K | ▲ 53.15K |
| Quest Partners LLC | 5.99K | ▼ 20.77K |
| California State Teachers Retirement System | 3.95K | ▼ 1.02K |
Held by 114 ETFs
Biggest fund positions in RZLT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 2, 26 | ROBERTS BRIAN KENNETH | other | 3,062 |
| Jul 2, 26 | Elam Nevan C | other | 8,004 |
| Jul 2, 26 | Evans Daron | other | 3,062 |
| Mar 30, 26 | Evans Daron | buy | 10,000 |
| Mar 2, 26 | ROBERTS BRIAN KENNETH | other | 11,439 |
| Mar 2, 26 | Evans Daron | other | 11,438 |
| Mar 2, 26 | Elam Nevan C | other | 27,618 |
| Dec 16, 25 | Hogenhuis Wladimir | buy | 5,650 |
| Dec 16, 25 | ROBERTS BRIAN KENNETH | buy | 28,000 |
| Dec 15, 25 | Evans Daron | buy | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RZLT coverage
Recent articles, reports, and earnings notes.
No research on RZLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RZLT report →Rezolute to Participate in the BTIG Virtual Biotechnology Conference
globenewswire.com · Jul 21
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
globenewswire.com · Jun 17
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
zacks.com · Jun 4
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
globenewswire.com · Jun 4
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
benzinga.com · Jun 2
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
globenewswire.com · Jun 2
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
globenewswire.com · May 12
Rezolute to Participate in Upcoming Investor Conferences
globenewswire.com · May 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.